Investor updates Suchbegriff Suchen Löschen 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 17 September 2021 Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer mehr Published on: 17 September 2021 Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer mehr Published on: 15 September 2021 Roche opens access to pathology imaging tools to improve patient care mehr Published on: 9 September 2021 Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases mehr Published on: 7 September 2021 Reminder: Invitation to Roche’s Virtual Pharma Day - Tuesday, 14th September 2021 mehr Published on: 7 September 2021 Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers mehr Published on: 27 August 2021 Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer mehr Published on: 18 August 2021 Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy mehr Published on: 9 August 2021 [Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care mehr Published on: 3 August 2021 US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer mehr Published on: 2 August 2021 FDA expands authorized use of REGEN-COV (casirivimab and imdevimab) mehr Published on: 30 Juli 2021 Invitation to Roche’s Virtual Pharma Day - Tuesday, 14th September 2021 mehr Published on: 29 Juli 2021 FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) mehr Published on: 29 Juli 2021 Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) mehr Published on: 22 Juli 2021 [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results mehr Published on: 21 Juli 2021 FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes mehr Published on: 20 Juli 2021 Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 mehr Published on: 19 Juli 2021 New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A mehr Published on: 16 Juli 2021 Reminder: Invitation to Roche’s Half Year Results 2021 Presentation mehr Published on: 9 Juli 2021 WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis mehr Published on: 2 Juli 2021 Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care mehr Published on: 30 Juni 2021 Atea’s AT-527, an oral antiviral drug candidate reduces viral replication in hospitalized patients with COVID-19 in phase 2 interim analysis mehr Published on: 28 Juni 2021 Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) mehr Published on: 25 Juni 2021 Invitation to Roche’s Half Year Results 2021 Presentation mehr Published on: 25 Juni 2021 Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children mehr Published on: 24 Juni 2021 FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) mehr Published on: 23 Juni 2021 Chugai obtains regulatory approval for Evrysdi for the treatment of Spinal Muscular Atrophy mehr Published on: 16 Juni 2021 REGEN-COV™ (casirivimab and imdevimab) phase 3 RECOVERY trial meets primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2 mehr Published on: 15 Juni 2021 Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio mehr Published on: 11 Juni 2021 Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia mehr Published on: 11 Juni 2021 New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) mehr Published on: 8 Juni 2021 Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home mehr Published on: 7 Juni 2021 Reminder: Invitation to Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting mehr Published on: 4 Juni 2021 Roche presents data on giredestrant, a next generation selective oestrogen receptor degrader for people with hormone receptor-positive, HER-2 negative breast cancer mehr Published on: 4 Juni 2021 Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma mehr Published on: 31 Mai 2021 Reminder: Invitation to Roche’s virtual event on key oncology data presented at 2021 ASCO Annual Meeting mehr Published on: 26 Mai 2021 Invitation to Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting mehr Published on: 25 Mai 2021 European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy mehr Published on: 20 Mai 2021 Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning mehr Published on: 11 Mai 2021 Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer mehr Published on: 5 Mai 2021 Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer mehr Published on: 30 April 2021 Invitation to Roche’s virtual event on key oncology data presented at 2021 ASCO Annual Meeting mehr Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer mehr Published on: 28 April 2021 Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people mehr Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer mehr Published on: 23 April 2021 Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia mehr Published on: 23 April 2021 CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) mehr Published on: 23 April 2021 Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy mehr Published on: 22 April 2021 Roche purchases shares in tender offer for GenMark Diagnostics, Inc. mehr Published on: 21 April 2021 Roche reports solid results in the first quarter of 2021 mehr Published on: 16 April 2021 New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis mehr Published on: 15 April 2021 Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) mehr Published on: 14 April 2021 Reminder: Invitation to Roche’s First Quarter Sales 2021 Webinar mehr Published on: 13 April 2021 FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications mehr Published on: 12 April 2021 Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% mehr Published on: 8 April 2021 New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio mehr Published on: 7 April 2021 Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types mehr Published on: 31 März 2021 Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging mehr Published on: 30 März 2021 Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy mehr Published on: 26 März 2021 Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer mehr Published on: 25 März 2021 Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash mehr Published on: 24 März 2021 Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan mehr Published on: 23 März 2021 Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency mehr Published on: 23 März 2021 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 mehr Published on: 22 März 2021 Roche provides update on tominersen programme in manifest Huntington’s disease mehr Published on: 22 März 2021 Invitation to Roche’s First Quarter Sales 2021 Webinar mehr Published on: 22 März 2021 Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning mehr Published on: 17 März 2021 Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs mehr Published on: 16 März 2021 Roche Annual General Meeting 2021 mehr Published on: 16 März 2021 Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations mehr Published on: 16 März 2021 New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) mehr Published on: 15 März 2021 Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives mehr Published on: 15 März 2021 Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample mehr Published on: 12 März 2021 Reminder: Invitation to Roche’s virtual event on 24-month data of Evrysdi in patients with type 2 or type 3 spinal muscular atrophy presented at the 2021 MDA virtual conference mehr Published on: 11 März 2021 Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems mehr Published on: 11 März 2021 Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia mehr Published on: 8 März 2021 Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives mehr Published on: 8 März 2021 Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer mehr Published on: 5 März 2021 Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition mehr Published on: 26 Februar 2021 Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany mehr Published on: 26 Februar 2021 EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 mehr Published on: 26 Februar 2021 Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older mehr Published on: 25 Februar 2021 Independent Data Monitoring Committee finds clear efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 outpatient outcomes trial mehr Published on: 25 Februar 2021 Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives mehr Published on: 25 Februar 2021 Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine mehr Published on: 19 Februar 2021 Invitation to Roche’s virtual event on 24-month data of Evrysdi in patients with type 2 or type 3 spinal muscular atrophy presented at the 2021 MDA virtual conference mehr Published on: 12 Februar 2021 New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients mehr Published on: 9 Februar 2021 Reminder: Invitation to Roche’s virtual event on key ophthalmology data presented at the Angiogenesis 2021 Meeting mehr Published on: 8 Februar 2021 FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients mehr Published on: 4 Februar 2021 Roche reports solid results in 2020 mehr Published on: 1 Februar 2021 Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection mehr Published on: 28 Januar 2021 Reminder: Invitation to Roche’s Full Year Results 2020 Presentation mehr Published on: 27 Januar 2021 REGEN-COV(TM) antibody cocktail is active against SARS-CoV-2 variants first identified in the UK and South Africa mehr Published on: 27 Januar 2021 Invitation to Roche’s virtual event on key ophthalmology data presented at the Angiogenesis 2021 Meeting mehr Published on: 26 Januar 2021 Regeneron reports positive interim data with REGEN-COV(TM) antibody cocktail used as passive vaccine to prevent COVID-19 mehr Published on: 25 Januar 2021 Roche renews partnership with Sysmex to deliver haematology testing solutions mehr Published on: 25 Januar 2021 Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration mehr Published on: 21 Januar 2021 FDA grants priority review to Roche’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease mehr Published on: 18 Januar 2021 Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy mehr Published on: 12 Januar 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab mehr Published on: 12 Januar 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer mehr Published on: 11 Januar 2021 Save the date: Roche Diagnostics Investor Day 2021 - Tuesday 23rd March 2021 mehr Published on: 11 Januar 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer mehr Published on: 11 Januar 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years mehr Published on: 5 Januar 2021 Invitation to Roche’s Full Year Results 2020 Presentation mehr Published on: 5 Januar 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer mehr
Published on: 17 September 2021 Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer mehr
Published on: 17 September 2021 Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer mehr
Published on: 15 September 2021 Roche opens access to pathology imaging tools to improve patient care mehr
Published on: 9 September 2021 Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases mehr
Published on: 7 September 2021 Reminder: Invitation to Roche’s Virtual Pharma Day - Tuesday, 14th September 2021 mehr
Published on: 7 September 2021 Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers mehr
Published on: 27 August 2021 Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer mehr
Published on: 18 August 2021 Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy mehr
Published on: 9 August 2021 [Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care mehr
Published on: 3 August 2021 US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer mehr
Published on: 30 Juli 2021 Invitation to Roche’s Virtual Pharma Day - Tuesday, 14th September 2021 mehr
Published on: 29 Juli 2021 FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) mehr
Published on: 29 Juli 2021 Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) mehr
Published on: 22 Juli 2021 [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results mehr
Published on: 21 Juli 2021 FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes mehr
Published on: 20 Juli 2021 Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 mehr
Published on: 19 Juli 2021 New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A mehr
Published on: 9 Juli 2021 WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis mehr
Published on: 2 Juli 2021 Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care mehr
Published on: 30 Juni 2021 Atea’s AT-527, an oral antiviral drug candidate reduces viral replication in hospitalized patients with COVID-19 in phase 2 interim analysis mehr
Published on: 28 Juni 2021 Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) mehr
Published on: 25 Juni 2021 Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children mehr
Published on: 24 Juni 2021 FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) mehr
Published on: 23 Juni 2021 Chugai obtains regulatory approval for Evrysdi for the treatment of Spinal Muscular Atrophy mehr
Published on: 16 Juni 2021 REGEN-COV™ (casirivimab and imdevimab) phase 3 RECOVERY trial meets primary outcome, improving survival in hospitalized COVID-19 patients lacking an immune response to SARS-CoV-2 mehr
Published on: 15 Juni 2021 Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio mehr
Published on: 11 Juni 2021 Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia mehr
Published on: 11 Juni 2021 New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) mehr
Published on: 8 Juni 2021 Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home mehr
Published on: 7 Juni 2021 Reminder: Invitation to Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting mehr
Published on: 4 Juni 2021 Roche presents data on giredestrant, a next generation selective oestrogen receptor degrader for people with hormone receptor-positive, HER-2 negative breast cancer mehr
Published on: 4 Juni 2021 Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma mehr
Published on: 31 Mai 2021 Reminder: Invitation to Roche’s virtual event on key oncology data presented at 2021 ASCO Annual Meeting mehr
Published on: 26 Mai 2021 Invitation to Roche’s virtual event on key Evrysdi data presented at the 2021 CureSMA Annual Meeting mehr
Published on: 25 Mai 2021 European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy mehr
Published on: 20 Mai 2021 Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning mehr
Published on: 11 Mai 2021 Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer mehr
Published on: 5 Mai 2021 Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer mehr
Published on: 30 April 2021 Invitation to Roche’s virtual event on key oncology data presented at 2021 ASCO Annual Meeting mehr
Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer mehr
Published on: 28 April 2021 Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people mehr
Published on: 28 April 2021 US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer mehr
Published on: 23 April 2021 Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia mehr
Published on: 23 April 2021 CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) mehr
Published on: 23 April 2021 Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy mehr
Published on: 22 April 2021 Roche purchases shares in tender offer for GenMark Diagnostics, Inc. mehr
Published on: 16 April 2021 New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis mehr
Published on: 15 April 2021 Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) mehr
Published on: 13 April 2021 FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications mehr
Published on: 12 April 2021 Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% mehr
Published on: 8 April 2021 New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio mehr
Published on: 7 April 2021 Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types mehr
Published on: 31 März 2021 Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging mehr
Published on: 30 März 2021 Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy mehr
Published on: 26 März 2021 Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer mehr
Published on: 25 März 2021 Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash mehr
Published on: 24 März 2021 Chugai: Polivy approved for treatment of relapsed or refractory diffuse large B-cell lymphoma in Japan mehr
Published on: 23 März 2021 Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency mehr
Published on: 23 März 2021 New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19 mehr
Published on: 22 März 2021 Roche provides update on tominersen programme in manifest Huntington’s disease mehr
Published on: 22 März 2021 Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning mehr
Published on: 17 März 2021 Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs mehr
Published on: 16 März 2021 Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations mehr
Published on: 16 März 2021 New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA) mehr
Published on: 15 März 2021 Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives mehr
Published on: 15 März 2021 Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample mehr
Published on: 12 März 2021 Reminder: Invitation to Roche’s virtual event on 24-month data of Evrysdi in patients with type 2 or type 3 spinal muscular atrophy presented at the 2021 MDA virtual conference mehr
Published on: 11 März 2021 Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems mehr
Published on: 11 März 2021 Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia mehr
Published on: 8 März 2021 Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives mehr
Published on: 8 März 2021 Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer mehr
Published on: 5 März 2021 Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition mehr
Published on: 26 Februar 2021 Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany mehr
Published on: 26 Februar 2021 EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 mehr
Published on: 26 Februar 2021 Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older mehr
Published on: 25 Februar 2021 Independent Data Monitoring Committee finds clear efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 outpatient outcomes trial mehr
Published on: 25 Februar 2021 Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives mehr
Published on: 25 Februar 2021 Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine mehr
Published on: 19 Februar 2021 Invitation to Roche’s virtual event on 24-month data of Evrysdi in patients with type 2 or type 3 spinal muscular atrophy presented at the 2021 MDA virtual conference mehr
Published on: 12 Februar 2021 New phase III data show Roche’s faricimab is the first investigational injectable eye medicine to extend time between treatments up to four months in two leading causes of vision loss, potentially reducing treatment burden for patients mehr
Published on: 9 Februar 2021 Reminder: Invitation to Roche’s virtual event on key ophthalmology data presented at the Angiogenesis 2021 Meeting mehr
Published on: 8 Februar 2021 FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients mehr
Published on: 1 Februar 2021 Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection mehr
Published on: 28 Januar 2021 Reminder: Invitation to Roche’s Full Year Results 2020 Presentation mehr
Published on: 27 Januar 2021 REGEN-COV(TM) antibody cocktail is active against SARS-CoV-2 variants first identified in the UK and South Africa mehr
Published on: 27 Januar 2021 Invitation to Roche’s virtual event on key ophthalmology data presented at the Angiogenesis 2021 Meeting mehr
Published on: 26 Januar 2021 Regeneron reports positive interim data with REGEN-COV(TM) antibody cocktail used as passive vaccine to prevent COVID-19 mehr
Published on: 25 Januar 2021 Roche renews partnership with Sysmex to deliver haematology testing solutions mehr
Published on: 25 Januar 2021 Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration mehr
Published on: 21 Januar 2021 FDA grants priority review to Roche’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease mehr
Published on: 18 Januar 2021 Roche Annual General Meeting 2021: Exercising of shareholder rights via the independent proxy mehr
Published on: 12 Januar 2021 Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab mehr
Published on: 12 Januar 2021 Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer mehr
Published on: 11 Januar 2021 Save the date: Roche Diagnostics Investor Day 2021 - Tuesday 23rd March 2021 mehr
Published on: 11 Januar 2021 Roche launches two digital pathology image analysis algorithms for precision patient diagnosis in breast cancer mehr
Published on: 11 Januar 2021 Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years mehr
Published on: 5 Januar 2021 Roche’s novel anti-TIGIT tiragolumab granted FDA Breakthrough Therapy Designation in combination with Tecentriq for PD-L1-high non-small cell lung cancer mehr